MRC Epidemiology Unit - Publications Database

The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.

Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, Lau ESH, Eliasson B, Kong APS, Ezzati M, Aguilar-Salinas CA, McGill M, Levitt NS, Ning G, So WY, Adams J, Bracco P, Forouhi NG, Gregory GA, Guo J, Hua X, Klatman EL, Magliano DJ, Ng BP, Ogilvie D, Panter J, Pavkov M, Shao H, Unwin N, White M, Wou C, Ma RCW, Schmidt MI, Ramachandran A, Seino Y, Bennett PH, Oldenburg B, Gagliardino JJ, Luk AOY, Clarke PM, Ogle GD, Davies MJ, Holman RR, Gregg EW

Lancet (London, England). Nov 2019

(DOI : 10.1016/S0140-6736(20)32374-6)

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT.

Griffin SJ, Bethel MA, Holman RR, Khunti K, Wareham N, Brierley G, Davies M, Dymond A, Eichenberger R, Evans P, Gray A, Greaves C, Harrington K, Hitman G, Irving G, Lessels S, Millward A, Petrie JR, Rutter M, Sampson M, Sattar N, Sharp S

Health technology assessment (Winchester, England). Apr 2018

(DOI : 10.3310/hta22180)

The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: A cluster randomised sub-study.

Farmer AJ, Oke J, Hardeman W, Tucker L, Sutton S, Kinmonth AL, Griffin SJ, Holman RR

Diabetes Research and Clinical Practice. Apr 2016

(DOI : 10.1016/j.diabres.2016.07.004)

Impact of personalized cardiovascular disease risk estimates on physical activity-a randomized controlled trial.

Price HC, Griffin SJ, Holman RR

Diabetic medicine : a journal of the British Diabetic Association. Feb 2011

(DOI : 10.1111/j.1464-5491.2010.03212.x)

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.

Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ

Lancet (London, England). Apr 2010

(DOI : 10.1016/S0140-6736(09)62162-0)

Perceptions of heart attack risk amongst individuals with diabetes.

Price HC, Dudley C, Barrow B, Griffin SJ, Holman RR

Primary care diabetes. Jul 2009

(DOI : 10.1016/j.pcd.2009.09.005)

Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes.

Price HC, Dudley C, Barrow B, Kennedy I, Griffin SJ, Holman RR

Family practice. Jun 2009

(DOI : 10.1093/fampra/cmp041)

Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort.

Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, Griffin SJ

Diabetes care. Dec 2008

(DOI : 10.2337/dc08-1918)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Califf RM, Boolell M, Haffner SM, Bethel M, McMurray J, Duggal A, Holman RR

American heart journal. Oct 2008

(DOI : 10.1016/j.ahj.2008.05.017)

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 x 2 factorial understanding risk trial.

Price HC, Tucker L, Griffin SJ, Holman RR

Cardiovascular diabetology. May 2008

(DOI : 10.1186/1475-2840-7-21)